

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

5  
Applicant : Clarence N. Ahlem, et al.  
Application No. : 10/607,035  
Filed : June 25, 2003  
Title : Pharmaceutical Compositions and Treatment Methods - 4  
10 Examiner : Barbara P. Badio  
  
Art Unit : 1616  
Customer No. : 26551  
Confirmation No. : 6394  
15

---

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT**

20 Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

25  
Dear Sir:

Applicants submit this paper in response to the restriction requirement the  
Office mailed on September 9, 2004. Applicants respectfully request the  
30 Examiner to enter the following amendments before examination on the merits.  
The amendments introduce no new matter. Provision for extension of time  
accompanies this paper.

Amendments to the claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.

02/08/2005 NVILLARI 00000004 501536 10607035

01 FC:2202 75.00 DA

Claim	Support
66, 67 73	named trisubstituted compounds: 3 $\beta$ , 16 $\alpha$ , 17 $\beta$ -trihydroxy-5 $\alpha$ -androsterone is compound 1.1.6.2 in group 1 at paragraphs 156 and 157; 3 $\alpha$ , 16 $\beta$ , 17 $\beta$ -trihydroxy-5 $\alpha$ -androsterone is compound 1.1.6.2 in group 37 at paragraph 202, etc.
57, 61	support for atopic asthma and other listed inflammation conditions is at paragraphs 319, 526, etc.
68	support for formulations comprising one or more excipients is at paragraph 271, etc.
74, 75 76	support for parenteral, oral, buccal, sublingual, aerosol formulations is at paragraphs 271-273, etc.
75	support for non-aqueous formulations containing less than 0.3% v/v water is at paragraph 366, etc.; support for suspension in an aqueous liquid formulation is at paragraph 273, etc.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 501536.

Respectfully submitted,

Hollis-Eden Pharmaceuticals, Inc.

Date: Dec 21, 2004 By: Daryl D Muenchau

Daryl D. Muenchau, Reg. No. 36,616  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, CA 92121  
P: 858-320-2569  
F: 858-558-6470